Recombinant Vesicular Stomatitis Virus Expressing Influenza Nucleoprotein Induces CD8 T-Cell Responses That Enhance Antibody-Mediated Protection after Lethal Challenge with Influenza Virus
- 1 April 2009
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 16 (4) , 488-498
- https://doi.org/10.1128/cvi.00451-08
Abstract
Live attenuated vaccine vectors based on recombinant vesicular stomatitis viruses (rVSVs) expressing foreign antigens are highly effective vaccines in animal models. In this study, we report that an rVSV expressing influenza nucleoprotein (VSV NP) from the first position of the VSV genome induces robust anti-NP CD8 T cells in immunized mice. These CD8 T cells are phenotypically similar to those induced by natural influenza infection and are cytotoxic in vivo. Animals immunized with an rVSV expressing the influenza hemagglutinin (rVSV HA) were protected but still exhibited considerable morbidity after challenge. Animals receiving a cocktail vaccine of rVSV NP and rVSV HA had reduced pulmonary viral loads, less weight loss, and reduced clinical signs of illness after influenza virus challenge, relative to those vaccinated with rVSV HA alone. Influenza NP is a highly conserved antigen, and induction of protective anti-NP responses may be a productive strategy for generating heterologous protection against divergent influenza strains.Keywords
This publication has 31 references indexed in Scilit:
- Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA AntigensPLOS ONE, 2008
- Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protectionVirology, 2007
- Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and FerretsPLoS Medicine, 2006
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- High-Level Primary CD8+T-Cell Response to Human Immunodeficiency Virus Type 1 Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis VirusesJournal of Virology, 2002
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Diminished Primary and Secondary Influenza Virus-Specific CD8+T-Cell Responses in CD4-Depleted Ig−/−MiceJournal of Virology, 2000
- Resistance to and Recovery from Lethal Influenza Virus Infection in B Lymphocyte–deficient MiceThe Journal of Experimental Medicine, 1997
- Recognition of Influenza A Virus Nucleoprotein by Human Cytotoxic T LymphocytesJournal of General Virology, 1986
- Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcriptionCell, 1981